i
Using the Food and Drug Administration’s Sentinel System for surveillance of TB infection
-
12 01 2022
-
-
Source: Int J Tuberc Lung Dis. 26(12):1170-1176
[PDF-333.29 KB]
Details:
-
Alternative Title:Int J Tuberc Lung Dis
-
Personal Author:
-
Description:SUMMARY
BACKGROUND:
We examined patterns in care for individuals treated for latent TB infection (LTBI) in the US Food and Drug Administration’s Sentinel System.
METHODS:
Using administrative claims data, we identified patients who filled standard LTBI treatment prescriptions during 2008–2019. In these cohorts, we assessed LTBI testing, clinical management, and treatment duration.
RESULTS:
Among 113,338 patients who filled LTBI prescriptions, 80% (90,377) received isoniazid (INH) only, 19% (21,235) rifampin (RIF) only, and 2% (1,726) INH+rifapentine (RPT). By regimen, the proportion of patients with documented prior testing for TBI was 79%, 54%, and 91%, respectively. Median therapy duration was 84 days (IQR 35–84) for the 3-month once-weekly INH+RPTregimen, 60 days (IQR 30–100) for the 6- to 9-month INH regimen, and 30 days (IQR 2–60) for the 4-month RIF regimen.
CONCLUSIONS:
Among the cohorts, INH-only was the most commonly prescribed LTBI treatment. Most persons who filled a prescription for LTBI treatment did not have evidence of completing recommended treatment duration. These data further support preferential use of shorter-course regimens such as INH+RPT.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:36447322
-
Pubmed Central ID:PMC9793953
-
Document Type:
-
Funding:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
